Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.

In the AXSANA/EUBREAST 3(R) study, researchers compared data about recurrence outcomes of more-invasive and less-invasive lymph node procedures.

A survey of practices that treat AYA patients with cancer showed that almost half of them screen for financial hardship, but few offer cancer-specific navigation.

HealthDay News — Artificial intelligence (AI)-based ambient scribes may reduce documentation time and improve physician well-being, according to a study published online Nov. 26 in NEJM AI.